BET Inhibitors as Anticancer Agents: A Patent Review

被引：21
作者：
Ali, Imran
Choi, Gildon [1 ]
Lee, Kwangho [1 ]
机构：
[1] Korea Res Inst Chem Technol, Bioorgan Sci Div, Daejeon 34114, South Korea
来源：
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY | 2017年 / 12卷 / 04期
关键词：
BET; BET inhibitors; BRDs; cancer; epigenetics; patent; therapeutic potential; BROMODOMAIN INHIBITORS; PROTEIN; TRANSCRIPTION; BINDING; FAMILY; IDENTIFICATION; ACETYLATION; RECOGNITION; CHROMATIN; BRD3;
D O I：
10.2174/1574892812666170808121228
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Bromodomain and Extra Terminal (BET) family of bromodomain proteins (BRDs), comprised of four members in humans (BRD2, BRD3, BRD4, and BRDT), has emerged as a promising new cancer target class for small-molecule drug discovery. Objective: This review discusses the patent literature of BET inhibitors (2010-2017) for the treatment of cancer and other related diseases. Method: BET proteins act as 'epigenetic readers' and bind to acetylated lysine residues on the tails of histones H3 and H4. Inhibition of BET proteins for a wide array of therapeutic applications has led to the discovery and development of various BET inhibitors. Results: The increasing significance of BET inhibitors as a potential anticancer therapeutic has led to an extensive patent activity both from academia and pharmaceutical industry. Several of the BET inhibitors are under clinical development for the treatment of various kinds of cancers. Conclusion: The unmet needs and challenges associated with BET inhibition for cancer treatment have been portrayed in this review. An insight into the current developments and future prospects has been described as well.
引用
收藏
页码：340 / 364
页数：25
相关论文
共 131 条
[1]  
Abbvie Inc, 2014, Patent No. [WO2014164780A1, 2014164780]
[2]  
AbbVie Inc, 2013, Bromodomain inhibitors, Patent No. [WO/2013/097601, 2013097601]
[3]  
Abbvie Inc, 2015, Patent No. [WO2015089075A1, 2015089075]
[4]  
Agustin C., 2016, Novel pyrido[2,3-b] pyrazinones as bet-family bromodomain inhibitors, Patent No. [WO2016203335, 2016203335]
[5]  
Aktoudianakis E., 2014, International Patent, Patent No. [WO 2014182929 Al, 2014182929]
[6]  
Albert J. S., 2014, Patent No. [WO2014152029A2, 2014152029]
[7]  
Albrecht B.K., 2012, Bromodomain Inhibitors and Uses Thereof, Patent No. [WO2012174487A2, 2012174487]
[8]  
Albrecht B. K., 2012, Patent No. [WO 2012/151512 A2, 2012151512]
[9]  
Albrecht B. K., 2012, Patent No. [WO 2012/075383 A2, 2012075383]
[10]   Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials [J].
Albrecht, Brian K. ;
Gehling, Victor S. ;
Hewitt, Michael C. ;
Vaswani, Rishi G. ;
Cote, Alexandre ;
Leblanc, Yves ;
Nasveschuk, Christopher G. ;
Bellon, Steve ;
Bergeron, Louise ;
Campbell, Robert ;
Cantone, Nico ;
Cooper, Michael R. ;
Cummings, Richard T. ;
Jayaram, Hariharan ;
Joshi, Shivangi ;
Mertz, Jennifer A. ;
Neiss, Adrianne ;
Normant, Emmanuel ;
O'Meara, Michael ;
Pardo, Eneida ;
Poy, Florence ;
Sandy, Peter ;
Supko, Jeffrey ;
Sims, Robert J., III ;
Harmange, Jean-Christophe ;
Taylor, Alexander M. ;
Audia, James E. .
JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (04) :1330-1339
12345678910